Creatv Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer Using a Simple Blood Test

Creatv Microtech has pioneered a blood test to predict treatment response in patients with stage II-III NSCLC treated with chemoradiation therapy and consolidated immunotherapy.
[Business Wire, Inc.]
Press Release
Bookmark

No account yet? Register

Share

Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology

Lassen Therapeutics announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology.
[Lassen Therapeutics]
Bookmark

No account yet? Register

Share

Bellicum Receives FDA IND Clearance to Initiate a Phase I/II Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors

Bellicum Pharmaceuticals, Inc. announced clearance by the FDA of its investigational new drug application for BPX-603. BPX-603 is a GoCAR-T® product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2).
[Bellicum Pharmaceuticals, Inc.]
Bookmark

No account yet? Register

Share

Immune Status Could Determine Efficacy of COVID-19 Therapies

Emerging evidence suggests that SARS-CoV-2 can drive a diverse array of immune processes, raising the risk that immunosuppressant agents that are in clinical trials might be effective for some patients but detrimental for others.
[Nature Reviews Drug Discovery]
Press Release
Bookmark

No account yet? Register

Share

How Deadly Is the Coronavirus? Scientists Are Close to an Answer

Researchers use a metric called infection fatality rate (IFR) to calculate how deadly a new disease is. It is the proportion of infected people who will die as a result, including those who don’t get tested or show symptoms.
[Nature News]
Press Release
Bookmark

No account yet? Register

Share

‘We’ve Got to Be Able to Move More Quickly.’ The Pandemic Reality of COVID-19 Clinical Trials

With speed borne of desperation comes risk and confusion—of trials too small to yield answers, of treatments overhyped, and of uncertainty about how to design the best studies possible. Science spoke with three clinical trial experts about this unprecedented period for modern medical research.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

Share

Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19

Adamis Pharmaceuticals Corporation announced a license to commercialize Tempol, a novel patented investigational drug for the treatment of COVID-19. The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.
[Adamis Pharmaceuticals]
Press Release
Bookmark

No account yet? Register

Share

Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in US FDA Phase II COVID-19 ARDS Trial

Pluristem Therapeutics, Inc. announced the activation of clinical sites and initiation of enrollment in its Phase II US FDA study of PLX cells for the treatment of severe COVID-19 complicated by Acute Respiratory Distress Syndrome (ARDS).
[Pluristem Therapeutics, Inc. ]
Graphical Abstract
Bookmark

No account yet? Register

Share

UCLA Receives Nearly $14 Million from NIH to Investigate Gene Therapy to Combat HIV

University of California, Lost Angeles (UCLA) researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.
[Univesity of California, Los Angeles]
Graphical Abstract
Bookmark

No account yet? Register

Share

CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin

CNS Pharmaceuticals, Inc. announced that the FDA has granted Orphan Drug Designation for its lead product Berubicin for the treatment of malignant gliomas.
[CNS Pharmaceuticals, Inc.]
Press Release
Bookmark

No account yet? Register

Share
Share